mitoxantrone hydrochloride liposome + PD-1 inhibitor

Mitoxantrone hydrochloride liposome + PD-1 inhibitor is a combination chemo-immunotherapy regimen being investigated for the treatment of recurrent or metastatic nasopharyngeal carcinoma (NPC). The regimen consists of a liposomal formulation of mitoxantrone, a synthetic anthracenedione that inhibits topoisomerase II and intercalates into DNA to induce cell death, and a PD-1 inhibitor (such as tislelizumab, camrelizumab, or toripalimab) which blocks the programmed cell death protein 1 receptor to restore anti-tumor T-cell activity. This specific combination is being evaluated in a Phase 2 clinical trial (NCT05482243) led by Ming-Yuan Chen at the Sun Yat-sen University Cancer Center, specifically targeting patients who have progressed after standard platinum-based chemotherapy and/or prior immunotherapy. The liposomal delivery of mitoxantrone is designed to improve the drug's pharmacokinetic profile and reduce cardiotoxicity compared to the conventional formulation.

Brand names

Duoenda

Other names

Mitoxantrone hydrochloride liposome injection combined with PD-1 blockadeMitoxantrone Liposome + PD-1 Blockade